What kind of name is on a peptide vial

Five kinds of name, and they are not interchangeable

One substance can be written five ways, and each way answers a different question.

There is the systematic chemical name, which describes the structure and is usually too long to print. There is a laboratory or sponsor code, normally some letters and a number, assigned by whoever was working on the compound. There is a nonproprietary name, the short lowercase word that scientific writing and prescribing use. There is a proprietary name, owned as a trademark by the company selling the product. And there is a compendial title, the heading a substance appears under in an official reference book.

A product page usually prints one of these and lets the reader assume it is the name. It rarely says which of the five it is.

That matters because the five have different origins and different weight. Two of them come from an organized process with a body behind it. Two of them belong to whoever claimed them. One of them is simply a description.

Where a nonproprietary name actually comes from

The short lowercase name is not chosen by the manufacturer alone, and it is not chosen by a regulator either.

Internationally it comes from the World Health Organization, which runs a program for International Nonproprietary Names. That program works with national naming committees to select a single name of worldwide acceptability for each active substance intended to be marketed as a pharmaceutical. Its stated position is that each such name is a unique name, globally recognized, and public property. A nonproprietary name is also known as a generic name.

The program uses shared word endings to group substances, and it asks that trademarks not be derived from those names or built from the endings the naming system reserves. That is why several compounds acting on a similar target tend to end the same way, and why the ending is a clue rather than a coincidence.

In the United States the equivalent body is the United States Adopted Names Council, and federal regulation describes it in unusually candid terms. It is a private organization, sponsored by the American Medical Association, the United States Pharmacopeia and the American Pharmaceutical Association, and it has been assigning names to drugs since January 1964. The regulation says the Council negotiates with manufacturing firms in the selection of nonproprietary names.

The regulation adds that the agency cooperates with the Council and is represented on it, and that applicants are encouraged to contact it. It also warns that prior use of a name in the medical literature will not commit the agency to adopting that terminology as official.

The two systems have converged. The World Health Organization records that national names, including the United States ones, are now identical to the international name with rare exceptions.

The name the statute cares about, and its three-step ladder

Federal law has a term for the name that is supposed to identify a drug. It is the established name, and the statute defines it as a ladder with three rungs.

The first rung is an official name designated by the Secretary under a separate section. The second rung applies if there is no such official name and the article is recognized in an official compendium, in which case the established name is the official title in that book. The third rung applies if neither of the first two does, and it reads: the common or usual name, if any.

Read the third rung twice. The law's last resort is whatever people call the thing, and the phrase "if any" is the statute conceding that there may be no such name at all.

The section that creates official names is worth knowing about, because it exists precisely for the problem described above. It lets the Secretary designate an official name where that is necessary or desirable in the interest of usefulness and simplicity. It anticipates two or more official names having been applied to a single drug, and it anticipates a medically useful drug having no name applied to it at all. It also says that an official name may not be established so as to infringe a valid trademark.

The agency has said it will not routinely use that power

The first rung of the ladder is mostly empty, and the reason is published rather than inferred.

The regulation on established names states that the agency will not routinely designate official names, and draws the consequence itself. As a result, it says, the established name will ordinarily be either the compendial name of the drug or, if there is no compendial name, the common and usual name.

The same regulation then tells interested persons what to rely on in the meantime. Absent an official designation, they may treat the current compendial name, or the adopted name listed in the dictionary the naming council publishes, as the established name.

It reserves the power for three situations. Where an existing name is unduly complex or otherwise not useful. Where two or more names have been applied to one drug. And where a medically useful drug has no name at all.

So the ladder resolves, for almost everything, to rung two or rung three. Either a reference book gave the substance a title, or people call it something.

What a code name is, and what nothing about it means

A great deal of what this market sells is known by a laboratory code: some letters, a hyphen, a number. The letters often stand for a project, an institution or a description, and the number is a series position.

Nobody issues those. There is no register of them, no body that approves them, and no rule against two different groups using the same one. A code was a filing convention that escaped into commerce.

This is the practical difference between the name of an approved medicine and the name on most peptide listings. One went through a naming process that involved a nomenclature committee and produced a name deliberately made unique. The other is a label somebody wrote on a batch.

That is not an accusation about any product. It is an explanation of why the same substance can appear under a code, under a nonproprietary name, and under a trademark all at once, with different amounts of evidence attached to each. A worked example of exactly that split, and what it does to the evidence, is set out in the article on the compound sold as PT-141.

A proprietary name has to travel with the other one, on a label the rule reaches

Where the established-name rule does apply, it is strict about the relationship between the two names.

For a prescription drug, the established name must be printed prominently and in type at least half as large as any proprietary name used for it. The implementing regulation goes further. The established name has to accompany the proprietary name each time that name is featured, placed in direct conjunction with it. The relationship has to be made clear by a phrase such as "brand of" preceding it, by brackets, or by other suitable means.

It also has to have a prominence commensurate with the proprietary name, taking into account typography, layout, contrast and other printing features. And the label must bear the established name to the exclusion of any other nonproprietary name, with an exception for the systematic chemical name or the chemical formula.

That last exception is worth noticing on its own. The statute treats a chemical formula as a different kind of thing from a name, and permits it alongside. What a formula settles and what it leaves undecided has its own article here.

Why none of that governs the vial you are handed

This is the part that reverses the expectation, and it is the reason a dispensed vial can carry a name no rule chose.

A drug dispensed by filling a prescription is exempt from the requirements of the misbranding section, with a short list of exceptions. The exemption is conditioned on the label bearing five stated items. Those are the dispenser's name and address, and the serial number and date of the prescription or of its filling. They also include the prescriber's name, the patient's name if the prescription stated it, and the directions and cautionary statements the prescription contained.

The exceptions preserved from that exemption are paragraphs (a), (i)(2) and (3), (k) and (l), plus the packaging requirements of three others. The established-name paragraph is not among them.

So the naming hierarchy above describes the label of a drug moving in commerce, not the label on a dispensed prescription. The regulation on established names is written under that same paragraph, so it does not reach that vial either.

What does survive the exemption is the first paragraph of the section, which deems a drug misbranded if its labeling is false or misleading in any particular. That is a standard about truth, not about typography. It sets no format, prescribes no name, and requires no hierarchy.

The dispensed label has its own separate list of required content, and that list has its own article here.

Telling the five apart in about a minute

Letters and digits joined by a hyphen, with no meaning outside the compound itself, are almost always a laboratory code.

A single lowercase word, often long, sharing an ending with other substances in the same family, is almost always a nonproprietary name. Those endings are the naming system at work.

A short capitalized invented word, unique, and often followed by a symbol claiming trademark rights, is a proprietary name. It belongs to a company, not to the substance.

A name followed by the initials of a reference book is a compendial title, and using it makes a specific claim about complying with that book. What that claim commits a seller to is set out separately here.

A string of element symbols and numbers is a formula, and a string of three-letter groups is a sequence. Neither is a name.

What to do with a name before you compare two listings

Work out which of the five kinds you are reading, because a code and a nonproprietary name do not carry the same weight of process behind them.

Check whether the two listings you are comparing are using the same kind of name for the same thing. A page selling under a code and a study written under a nonproprietary name may or may not be about one substance, and the names alone will not tell you.

Treat a trademark as information about a company rather than about a molecule. It says who is selling, not what is inside.

Where a name is the only identifier on offer, ask for the ones that are not names: the sequence, the registry number, the salt or complex form. Those are a separate check and there is an article on it here.

Do not read the presence of an official-sounding name as approval, and do not read the absence of one as a finding about safety. Naming and approval are different processes run by different people.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. United States Code Title 21, Section 352, Misbranded drugs and devices, subsection (e) on designation of drugs by established names, including the three-part definition at (e)(3) and the half-size prominence requirement at (e)(1)(B), and subsection (a) on false or misleading labeling — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
2. United States Code Title 21, Section 358, Authority to designate official names, read in full including the trademark limitation in subsection (a) and the three triggers in subsection (c) — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
3. United States Code Title 21, Section 353(b)(2), exempting a drug dispensed by filling a prescription from the requirements of section 352 except the paragraphs it lists, on condition the label bears five stated items — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
4. Title 21 Code of Federal Regulations Section 299.4, Established names for drugs, read in full including the description of the United States Adopted Names Council in paragraph (c) and the statement in paragraph (e) that the agency will not routinely designate official names — Electronic Code of Federal Regulations, Office of the Federal Register, April 2004
5. Title 21 Code of Federal Regulations Section 201.10, Drugs; statement of ingredients, paragraph (g) on the placement, size and prominence of an established name beside a proprietary name — Electronic Code of Federal Regulations, Office of the Federal Register, June 2024